What this page establishes
- The Wegovy prescribing information reports mean resting heart rate increases of 1 to 4 bpm versus placebo in weight-management trials.
- The label instructs clinicians to monitor heart rate at regular intervals, tells patients to report palpitations or a racing heartbeat at rest, and says to discontinue if there is a sustained increase in resting heart rate.
- In SELECT (17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo.
- A prespecified SELECT analysis found benefit consistent across baseline weight and waist-circumference categories, with roughly a third of the MACE benefit mediated through waist-circumference reduction, implying mechanisms beyond weight loss alone.
Quick answers
I only started tracking after I began treatment. How do I know what my baseline was?
You do not, and the label's comparison is against your own prior level. What is left is still usable: track the trend from where you are now, and rely on the symptom list rather than a single number.
Read the full answer
Palpitations or a racing heart at rest go to your prescriber regardless of what your first reading was.I take tirzepatide. Does the 20% figure apply to me?
No, that number belongs to semaglutide 2.4 mg in SELECT, in 17,604 adults with overweight or obesity and established cardiovascular disease and without diabetes.
Read the full answer
Cardiovascular outcome evidence does not transfer between molecules, and it does not transfer to a different population either. Ask what outcome trial exists for the drug you are actually on.I already have atrial fibrillation. Where does that leave me?
SELECT was not designed to answer arrhythmia questions, so its reassurance does not extend cleanly to yours.
Read the full answer
The labelled heart-rate effect is a normal item to raise at a cardiology review, where someone can read it against your particular heart. A change in your usual rhythm, or a new irregular pulse, is an assessment rather than a reassurance.
Your watch is probably right and the number is probably fine. The Wegovy prescribing information documents mean resting heart rate increases of 1 to 4 bpm versus placebo in the weight-management trials, so a small upward shift is expected rather than surprising. The second fact belongs beside the first: in SELECT, a trial of 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo. A faster resting pulse and fewer heart attacks are both in the data. This page keeps them separate, because people reading only one of them draw the wrong conclusion in both directions.
The size of the increase, and what the label says to do about it
A mean of 1 to 4 bpm. That is the labelled figure, measured against placebo across the weight-management trials.
The prescribing information also tells clinicians what to do with it. Monitor heart rate at regular intervals. Tell patients to report palpitations or a racing heartbeat at rest. Discontinue if there is a sustained increase in resting heart rate.
That third instruction is worth reading carefully, because it is often quoted as though it applies to any increase at all. The label distinguishes a sustained rise in resting heart rate, which is a discontinuation consideration for the prescriber, from occasional palpitations, which is something to report. Both route to your prescriber. Neither routes to a forum.
The word doing the work is sustained. A mean effect of 1 to 4 bpm is, by definition, a shift most people will show to some degree. The label is not asking prescribers to stop treatment over that. It is asking them to look at whether a particular patient has moved well outside it and stayed there.
Why a GLP-1 raises heart rate at all
GLP-1 receptors are present in the sinoatrial node and in autonomic centres, and receptor activation produces a small positive chronotropic effect that is independent of weight change. Sympathetic activation and reduced parasympathetic tone have both been proposed as contributing mechanisms.
The magnitude is the point. One to four beats is inside the range your wearable will swing across an ordinary week for reasons like sleep debt, a glass of wine, a head cold or a warm bedroom.
Blood pressure moves the other way. Weight loss lowers systolic and diastolic pressure, so the overall haemodynamic picture is a slightly faster circulation running at lower pressure. That combination is not the same as a stressed cardiovascular system, and it is one reason the small heart-rate signal did not become a harm signal in the outcome data.
It is worth being clear that the chronotropic effect is not simply a consequence of losing weight. Receptor activation produces it directly, which is why it appears early, before much weight has come off, and why it does not resolve as the scale falls. People expecting it to fade as they get lighter are working from the wrong model.
What SELECT found on hard outcomes
SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes. Semaglutide 2.4 mg cut major adverse cardiovascular events by 20% against placebo.
A prespecified analysis found the benefit consistent across baseline weight and waist-circumference categories, with roughly a third of the MACE benefit mediated through waist-circumference reduction. Two-thirds therefore came from somewhere other than the amount of fat lost, which points at mechanisms beyond weight itself.
Another prespecified analysis looked at participants with prevalent heart failure at baseline and found cardiovascular benefit consistent in that subgroup, which is the population where a heart-rate rise would worry a cardiologist most.
Size matters when you weigh these two findings against each other. The heart-rate effect is a mean of a few beats with no demonstrated outcome consequence. The MACE finding is a hard endpoint, prespecified, in 17,604 people, with a 20% relative reduction. Those are not comparable levels of evidence and they should not be given comparable weight in a decision.
Reading your wearable without scaring yourself
Wearable resting heart rate is a noisy signal read best as a trend over weeks against your own pre-treatment baseline. A single morning reading tells you about that morning, and not much else.
The comparison that carries information is your own history, not a population norm. Wrist-based optical sensors also disagree with each other and with a chest strap, so switching devices mid-treatment introduces a step change that looks like a drug effect and is not one.
A rise of a few beats after starting is what the label predicts. Caffeine, dehydration, poor sleep and GI illness all raise resting heart rate independently, and all four are unusually common in the first weeks on a GLP-1, so the early period is exactly when your data are noisiest.
The number that deserves attention is a persistent elevation well above your own baseline that does not settle, rather than a few beats that appeared during titration. If you are unsure which one you are looking at, the label's answer is to take it to your prescriber.
| What you see | How the label frames it | What it routes to |
|---|---|---|
| Resting HR up 1 to 4 bpm after starting | The documented mean effect | Expected. Keep tracking the trend |
| Occasional palpitations or racing heart at rest | Report to your prescriber | Prescriber conversation |
| A sustained increase in resting heart rate | A reason to consider discontinuation | Prescriber decision, not yours |
| Chest pain, fainting or near-fainting | Outside the heart-rate discussion entirely | Urgent medical assessment |
Existing cardiac disease, heart failure and arrhythmia
The reassuring datapoint for people with existing disease is that SELECT enrolled exactly that population. Everyone in it had established cardiovascular disease, and the prespecified heart-failure subgroup analysis found benefit consistent there too.
That is not the same as saying every cardiac condition is covered. Arrhythmia specifically is not something SELECT was designed to answer, and a new irregular pulse is a reason for assessment rather than reassurance.
If you are under cardiology care, the heart-rate item on the label is a normal thing to raise at a review appointment. It is a known and documented effect, and your cardiologist will have an opinion about it in the context of your particular heart.
One framing helps here. The label instruction to monitor heart rate exists because the effect is real and worth watching, not because the trials found harm from it. SELECT is the largest test of whether that small chronotropic effect matters at the level of heart attacks and strokes, and the answer it returned was a 20% reduction in major adverse cardiovascular events.
Exercise heart rate and training zones
Zone boundaries derived from a resting or maximal test done before starting will be slightly off once the resting baseline has moved. This shows up most obviously as easy sessions reading a zone higher than they used to.
Re-testing after titration settles is the straightforward fix, and it is what many coaches do rather than assume the old numbers still hold.
Effort at a given pace may also genuinely be higher for reasons that have nothing to do with heart rate, because a sustained energy deficit means glycogen is less reliably topped up. The running page covers that in detail.
Maximum heart rate is a separate question and the trials do not answer it. What the labelling documents is a resting effect. If your peak readings in hard sessions look unchanged while resting readings have crept up, that is consistent with the labelled picture rather than at odds with it.
Things that raise resting heart rate and are not the drug
Worth ruling these out before concluding anything, particularly during the first weeks when several of them are likely to be true at once.
- Caffeine, especially at higher intake or later in the day
- Dehydration, which is common during a week of GI symptoms
- Poor or short sleep
- Any acute infection, including a minor one
- Alcohol the previous evening
- Anxiety about the reading itself, which is a real and underrated contributor
A first-person account, for context
Everything above is drawn from trial data and prescribing information. What that evidence cannot give you is what a GLP-1 block actually feels like week to week in someone training seriously.
Thomas Prommer, a competitive endurance athlete, has written up how the medication showed up in his training data. Read it as one person's experience rather than as evidence. It is n=1, it is uncontrolled, and it describes an athlete population the trials on this page did not study. It is useful for exactly that reason and for no other.
When to contact a clinician
Items three and four on this list are emergencies rather than appointments.
- A resting heart rate persistently well above your baseline, rather than a shift of a few beats
- Palpitations or a racing heart at rest, particularly with breathlessness
- Chest pain, fainting or near-fainting
- A new irregular pulse
- Any of the above alongside vomiting, diarrhoea or poor fluid intake, since dehydration compounds all of it
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| The Wegovy prescribing information reports mean resting heart rate increases of 1 to 4 bpm versus placebo in weight-management trials. | established | WEGOVY (semaglutide) US Prescribing Information, FDA |
| The label instructs clinicians to monitor heart rate at regular intervals, tells patients to report palpitations or a racing heartbeat at rest, and says to discontinue if there is a sustained increase in resting heart rate. | established | WEGOVY US Prescribing Information, FDA |
| In SELECT (17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo. | established | SELECT trial summary, American College of Cardiology |
| A prespecified SELECT analysis found benefit consistent across baseline weight and waist-circumference categories, with roughly a third of the MACE benefit mediated through waist-circumference reduction, implying mechanisms beyond weight loss alone. | established | Semaglutide and cardiovascular outcomes by adiposity measurements, The Lancet |
| A prespecified SELECT analysis in participants with prevalent heart failure found consistent cardiovascular benefit in that subgroup. | established | Semaglutide and cardiovascular outcomes in obesity with prevalent heart failure, The Lancet |
| The modest heart-rate increase seen across GLP-1 trials has not translated into adverse cardiovascular outcomes in any large outcome trial, including SELECT. | established | SELECT trial summary, ACC |
Sources
- WEGOVY (semaglutide) US Prescribing Information, FDA
- SELECT trial summary, American College of Cardiology
- Semaglutide and cardiovascular outcomes by adiposity measurements, The Lancet
- Semaglutide and cardiovascular outcomes in obesity with prevalent heart failure, The Lancet
Keep reading
- GLP-1 and Blood PressureBlood pressure falls, heart rate rises. Both are expected. The practical issue is antihypertensive doses set f
- GLP-1 and Running: Endurance Training, Pace and FuellingBody mass falls, which helps. Glycogen availability falls and resting heart rate rises, which hurts. Aerobic f
- GLP-1 and Caffeine: Heart Rate, Jitters and an Empty StomachThere is no documented drug interaction. There is a plausible additive effect on heart rate and on GI irritati
- GLP-1 and Diabetes: What Differs Between the T2D and Obesity IndicationsOzempic and Wegovy are the same molecule with different indications. The part that can hurt you is what happen
- GLP-1 and Kidney Health: Protection, and the Dehydration WarningChronic protection and acute vulnerability at the same time. FLOW's benefit is specific to type 2 diabetes wit